Connect Biopharma Holdings Book Value Per Share Growth & History (CNTB)
Connect Biopharma Holdings's book value per share was $0.74 for fiscal 2025.
View full Connect Biopharma Holdings company overviewConnect Biopharma Holdings annual book value per share history
| Fiscal year | Period ended | Book value per share | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $0.74 | -$0.92 | −55.33% |
| 2024 | 2024-12-31 | $1.67 | -$0.18 | −9.60% |
| 2023 | 2023-12-31 | $1.84 | -$1.04 | −36.00% |
| 2022 | 2022-12-31 | $2.88 | -$2.07 | −41.77% |
| 2021 | 2021-12-31 | $4.94 | $14.13 | — |
| 2020 | 2020-12-31 | -$9.19 | — | — |
Connect Biopharma Holdings quarterly book value per share
| Fiscal quarter | Period ended | Book value per share | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $0.43 | -$0.86 | −66.77% |
| Q1 2026 | 2026-03-31 | $0.68 | -$0.82 | −54.62% |
| Q4 2025 | 2025-12-31 | $0.74 | -$0.92 | −55.33% |
| Q3 2025 | 2025-09-30 | $0.99 | — | — |
| Q2 2025 | 2025-06-30 | $1.28 | -$0.72 | −36.07% |
| Q1 2025 | 2025-03-31 | $1.50 | — | — |
| Q4 2024 | 2024-12-31 | $1.67 | -$0.18 | −9.60% |
| Q2 2024 | 2024-06-30 | $2.01 | -$0.33 | −14.07% |
| Q4 2023 | 2023-12-31 | $1.84 | -$1.04 | −36.00% |
| Q2 2023 | 2023-06-30 | $2.34 | -$1.54 | −39.65% |
| Q4 2022 | 2022-12-31 | $2.88 | — | — |
| Q2 2022 | 2022-06-30 | $3.87 | — | — |
Connect Biopharma Holdings book value per share trends
Over the last five fiscal years, Connect Biopharma Holdings's book value per share increased from -$9.19 to $0.74, a change of $9.94. The latest reported quarter, Q2 2026, shows $0.43.
What book value per share means
Book value per share estimates the common shareholders’ accounting equity represented by each share. It can help compare a company’s balance-sheet value over time, although market value can differ substantially from book value.
How book value per share is calculated
TickerStat calculates book value per share as SEC-reported common shareholders’ equity divided by reported period-end common shares. Preferred equity is subtracted when separately reported, and basic weighted-average shares are used only when period-end shares are unavailable. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Connect Biopharma Holdings source filings ↗